Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 1, 2026, Erasca, Inc. (ERAS) has a Wall Street consensus price target of $9.60, based on estimates from 9 covering analysts. With the stock currently trading at $13.66, this represents a potential downside of -29.7%. The company has a market capitalization of $3.88B.
Analyst price targets range from a low of $5.00 to a high of $12.00, representing a 73% spread in expectations. The median target of $10.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 7 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ERAS trades at a trailing P/E of -19.8x. Analysts expect EPS to grow -3.6% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how ERAS stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonERAS's consensus price target is $9.6, -29.7% below the current price of $13.66. The 9 analysts tracking ERAS see downside risk at present valuations.
ERAS has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 7 Buy/Strong Buy ratings. The consensus 12-month price target of $9.6 implies -29.7% downside from current levels.
ERAS's current price is $13.66 with a consensus target of $9.6 (-29.7% implied move). Analyst estimates suggest the stock is overvalued at current levels.
The most bullish Wall Street analyst has a price target of $12 for ERAS, while the most conservative target is $5. The consensus of $9.6 represents the median expectation. These targets typically reflect 12-month expectations.
ERAS is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 7 have Buy ratings, 1 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ERAS stock forecast based on 9 Wall Street analysts shows a consensus price target of $9.6, with estimates ranging from $5 (bear case) to $12 (bull case). The median consensus rating is "Buy".
Analysts are cautious on ERAS, with 1 Sell ratings and a price target of $9.6 (-29.7% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ERAS analyst price targets range from $5 to $12, a 73% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $9.6 consensus represents the middle ground.